OPTUM®

Specialty Rx Analytic IQ Suite Overview

Our solution

- Optum brings forward a new method of accurate payments under the medical benefit for specialty drugs.
- Leveraging clinical and technical experts, in addition to our proven Payment Integrity Platforms, Optum® identifies, defines, manages and implements specific criteria for specialty medications based on the following criteria:
  - Duration of treatment course
  - Dosage minimums and maximums
  - Frequency of dosing
  - Gender appropriateness
  - Duplication of therapy
  - Pricing
  - Contraindications to condition
  - Evidenced-based diagnoses
  - Contraindications to treatment
- Optum will review your specialty drug spend in order to configure the rule set to align with your policy and utilization:
  - Optum has an established specialty medications list ready for deployment.
  - Optum has flexible deployment allowing for review and implementation of new rules based on your specialty drug target.
- Clinical criteria are developed and maintained by a team clinical experts:
  - Dedicated physicians and pharmacists experts.
  - Edits and rules are based on extensive clinical research performed by credentialed coding experts with comprehensive claims analysis experience.
  - Clinical sources include U.S National Library of Medicine, Clinical Pharmacology, Lexicomp, Wolters Kluwer Clinical Drug Information, EncoderPro, FDA and CMS.
- Drug pricing edits will ensure accurate payment based on the dates of service.

Our capabilities

- Rules are developed, maintained and implemented by Optum Research and Development Team.
- Rules can be deployed in Data Driven Rules (DDR) environments.
- The flag is used to report back to the adjudication system and recommend action based on status or severity:
  - Deny
  - Review
  - Profile
- Transparency and disclosure:
  - Edits are sourced at the specific code relationship level (e.g., procedure code with age).
- The product will edit both Professional (1500) and Facility (UB) claims.
- Synchronization with your prior authorization process ensures medications are processed with appropriate approval.
- Synchronization with your pharmacy utilization ensures a single payment.
- Drugs are identified through NDCs and HCPCS (J-Codes).
- Analytics are built through HCPCS (J-Codes) and NDCs.
- Edits can be activated either by HCPCS (e.g. J codes) or NDC coming from the client's claims processing system.

Specialty drug edit list*

Rheumatoid Arthritis and Crohn's Disease
- abatacept (Orencia®)
- certolizumab (Cimzia®)
- golimumab (Simponi®)
- infliximab (Remicade® and biosimilars)
- rituximab (Rituxan®)
- tocilizumab (Actemra®)
- ustekinumab (Stelara®)
- vedolizumab (Entyvio®)

Immune Deficiency
- IVIG (e.g. Gammagard®, Flebogamma®, Carimune®)
- Bivigam®
- Cuvitru SQ®
- Flebogamma®
- Gamma Globulin
- Gammaplex®
- Gamunex®
- Hizentra®
- Immune Globulin
- Octagam®
- Privigen®

Multiple Sclerosis
- alemtuzumab (Lemtrada®)
- natalizumab (Tysabri®)
- ocrelizumab (Ocrevus®)

Pregnancy Complications
- hydroxyprogesterone caproate (Makena® generics)

Pregnancy Preventions
- etonogestrel implant (Nexplanon®)
- levonorgestrel releasing intrauterine contraceptive (e.g. Skyla®)
- medroxyprogesterone acetate IM (e.g. Depo Provera®)

Infection Preventions
- pegfilgrastim (Neulasta® and biosimilar)

Paroxysmal Nocturnal Hemoglobinuria (PNH)
- eculizumab (Soliris®)

Muscle Contractions
- abobotulinumtoxinA (Dysport®)
- incobotulinumtoxinA (Xeomin®)
- rimabotulinumtoxinB (Myobloc®)
- onabotulinumtoxinA (Botox®)

Hemophilia
- anti-inhibitor
- factor VII
- factor VIII (e.g. recombinant)
- factors (e.g. recombinant)
- hemophilia clotting factors, NOC

Angioedema
- C-1 esterase (Cinryze®)
- Human C-1 esterase inhibitor (Haegarda®, Berinert®)
- C-1 esterase inhibitor recombinant (Ruconest®)
- Ecallantide (Kalbitor®)
- icatibant (Firazyr®)

Cancers
- bevacizumab (Avastin®)

Macular Degeneration
- ranibizumab (Lucentis®)

* Specialty drug edit list last updated April 2019.

optum.com

11000 Optum Circle, Eden Prairie, MN 55344